Abstract:Our findings provide an efficient combination strategy for increasing clinically important daptomycin production by enhancing aspartate precursor supply, abolishing by‐product red pigment production, engineering daptomycin biosynthetic gene cluster (BGC) by promoter replacement, and duplicating the engineered daptomycin BGC in Streptomyces roseosporus wild‐type strain. We finally obtained a maximal DAP titre of 350.7 μg/mL, representing the highest reported titre in shake‐flask fermentation. Such strategies can be readily applied in the overproduction of other antibiotics using aspartate as a precursor. Daptomycin (DAP), a novel cyclic lipopeptide antibiotic produced by Streptomyces roseosporus, is clinically important for treatment of infections caused by multidrug‐resistant Gram‐positive pathogens, but the low yield hampers its large‐scale industrial production. Here, we describe a combination metabolic engineering strategy for constructing a DAP high‐yielding strain. Initially, we enhanced aspartate (Asp) precursor supply in S. roseosporus wild‐type (WT) strain by separately inhibiting Asp degradation and competitive pathway genes using CRISPRi and overexpressing Asp synthetic pathway genes using strong promoter kasOp*. The resulting strains all showed increased DAP titre. Combined inhibition of acsA4, pta, pyrB, and pyrC increased DAP titre to 167.4 μg/mL (73.5% higher than WT value). Co‐overexpression of aspC, gdhA, ppc, and ecaA led to DAP titre 168 μg/mL (75.7% higher than WT value). Concurrently, we constructed a chassis strain favourable for DAP production by abolishing by‐product production (i.e., deleting a 21.1 kb region of the red pigment biosynthetic gene cluster (BGC)) and engineering the DAP BGC (i.e., replacing its native dptEp with kasOp*). Titre for the resulting chassis strain reached 185.8 μg/mL. Application of our Asp precursor supply strategies to the chassis strain further increased DAP titre to 302 μg/mL (2.1‐fold higher than WT value). Subsequently, we cloned the engineered DAP BGC and duplicated it in the chassis strain, leading to DAP titre 274.6 μg/mL. The above strategies, in combination, resulted in maximal DAP titre 350.7 μg/mL (2.6‐fold higher than WT value), representing the highest reported DAP titre in shake‐flask fermentation. These findings provide an efficient combination strategy for increasing DAP production and can also be readily applied in the overproduction of other Asp‐related antibiotics.

Research Progress of Biosynthesis of Daptomycin and Its Derivative

Advances in daptomycin biosynthesis

Research Progress in Chemical Semi-synthetic Modification of Thiopeptide Antibiotics

In-Host Evolution of Daptomycin Resistance and Heteroresistance in Methicillin-Resistant Staphylococcus Aureus Strains from Three Endocarditis Patients

Regulation of daptomycin biosynthesis in Streptomyces roseosporus: new insights from genomic analysis and synthetic biology to accelerate lipopeptide discovery and commercial production

A facile and selective derivatization approach on kynurenine-NH 2 in daptomycin, leading to the discovery of hexakynomycin to combat multidrug-resistant Gram-positive pathogens especially daptomycin-resistant bacteria

Update on daptomycin: the first approved lipopeptide antibiotic

Daptomycin: Putative New Mechanisms of Action and Resistance Evolved from Transcriptome Data Mining

Daptomycin: Mechanism of action, mechanisms of resistance, synthesis and structure-activity relationships

Daptomycin: mechanisms of action and resistance, and biosynthetic engineering

Daptomycin: one of the cyclo-lipopeptide antibiotics

Improving the Yield and Quality of Daptomycin in Streptomyces Roseosporus by Multilevel Metabolic Engineering

Lipidation Engineering in Daptomycin Biosynthesis

Engineering of the start condensation domain with improved N‐decanoyl catalytic activity for daptomycin biosynthesis

Efficient bioconversion of daptomycin to its nucleus by heterologous expression of deacylase genes in Streptomyces

Progress in the Research of Biosynthesis of Tetracyclines

Chemical optimization and derivatization of micrococcin p2 to target multiple bacterial infections: new antibiotics from thiopeptides

Enhancing the antibacterial efficacy of vancomycin analogues: targeting metallo-β-lactamases and cell wall biosynthesis

Metabolic engineering of Streptomyces roseosporus for increased production of clinically important antibiotic daptomycin

Natural Products Resolve Antibiotic Resistance Crisis

Discovery and Derivatization of Tridecaptin Antibiotics with Altered Host Specificity and Enhanced Bioactivity